注射用尤瑞克林联合丁苯酞氯化钠注射液对急性脑梗死患者的影响

Effect of Urinary Kallidinogenase for Injection Combined with Butylphthalide and Sodium Chloride Injection on Patients with Acute Cerebral Infarction

目的:分析注射用尤瑞克林联合丁苯酞氯化钠注射液对急性脑梗死(ACI)患者的影响。方法:回顾性分析2022年8月—2023年7月漳浦县医院收治的160例ACI患者的临床资料。根据不同治疗方案将其分为对照组(n=80)和观察组(n=80)。对照组给予丁苯酞氯化钠注射液,观察组在对照组基础上给予注射用尤瑞克林。比较两组临床疗效,治疗前后神经功能及日常生活能力、脑血流动力学、相关指标及不良反应。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组美国国立卫生研究院脑卒中量表(NIHSS)评分降低,日常生活能力量表(ADL)评分升高,观察组NIHSS评分低于对照组,ADL评分高于对照组,差异有统计学意义(P<0.05)。治疗后,两组平均流速(Vm)均升高,搏动指数(PI)、阻力指数(RI)均降低,观察组Vm明显高于对照组,PI、RI均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组降钙素原(PCT)、C反应蛋白(CRP)水平均降低,观察组PCT、CRP水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用注射用尤瑞克林联合丁苯酞氯化钠注射液治疗ACI患者可提高治疗效果,改善脑血流动力学和抑制炎症反应,减轻神经功能缺损,且安全性好。

Objective:To analyze the effect of Urinary Kallidinogenase for Injection combined with Butylphthalide and Sodium Chloride Injection on patients with acute cerebral infarction(ACI).Method:The clinical data of 160 patients with ACI admitted to Zhangpu County Hospital from August 2022 to July 2023 were retrospectively analyzed.They were divided into control group(n=80)and observation group(n=80)according to different treatment regimens.The control group was given Butylphthalide and Sodium Chloride Injection,and the observation group was given Urinary Kallidinogenase for Injection on the basis of the control group.The clinical efficacy,neurological function and ability of daily living,cerebral hemodynamics,related indexes before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the score of National Institutes of Health stroke scale(NIHSS)decreased and the score of daily living ability scale(ADL)increased in both groups,the NIHSS score of the observation group was lower than that of the control group,and the ADL score was higher than that of the control group,the differences were statistically significant(P<0.05).After treatment,the mean flow velocity(Vm)of the two groups were increased,and the pulse index(PI)and resistance index(RI)were decreased,and the Vm of the observation group was significantly higher than that of the control group,and PI and RI were lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of procalcitonin(PCT)and C-reactive protein(CRP)in both groups were decreased,and the levels of PCT and CRP in observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Using the Urinary Kallidinogenase for Injection combined with Butylphthalide and Sodium Chloride Injection in the treatment of ACI patients can improve the therapeutic effect,improve the cerebral hemodynamics,inhibit the inflammatory response,reduce the neurological deficit,and have good safety.